Polar Asset Management Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Polar Asset Management Partners’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-242,300	Closed	-$3.57M	–	774
2023 Q4	$3.57M	Buy	242,300 +210,300	+657%	+$3.22M	0.06%	274
2023 Q3	$586K	Sell	32,000 -45,000	-58%	-$952K	0.01%	487
2023 Q2	$1.66M	Sell	77,000 -100,200	-57%	-$2.71M	0.03%	465
2023 Q1	$5.2M	Buy	+177,200	New	+$6.16M	0.08%	324

Other funds holding AMLX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Polar Asset Management Partners's AMLX Position: Q1 2024 in Review

Polar Asset Management Partners sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2024, closing a stake of 242,300 shares — an estimated $3.57M sold.

Polar Asset Management Partners first reported a position in AMLX in Q1 2023 and held it in 4 quarters. The position peaked at $5.2M in Q1 2023. 143 funds tracked by Wall St. Rank hold AMLX as of Q1 2024.

Polar Asset Management Partners reported no remaining Amylyx Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Polar Asset Management Partners sold 242,300 Amylyx Pharmaceuticals shares in Q1 2024, an estimated $3.57M.
Polar Asset Management Partners first reported a position in Amylyx Pharmaceuticals in Q1 2023 and held it in 4 quarters.
Polar Asset Management Partners's Amylyx Pharmaceuticals position peaked at $5.2M in Q1 2023.
143 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2024.

Based on Polar Asset Management Partners's 13F filing for Q1 2024, filed 15 May 2024.